- Home
- ACIC vs PLRX Comparison
ACIC vs PLRX Comparison
Compare ACIC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- PLRX
- Stock Information
- Founded
- ACIC 1999
- PLRX 2015
- Country
- ACIC United States
- PLRX United States
- Employees
- ACIC N/A
- PLRX N/A
- Industry
- ACIC Property-Casualty Insurers
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- PLRX Health Care
- Exchange
- ACIC Nasdaq
- PLRX Nasdaq
- Market Cap
- ACIC 556.0M
- PLRX 84.7M
- IPO Year
- ACIC N/A
- PLRX 2020
- Fundamental
- Price
- ACIC $11.04
- PLRX $1.29
- Analyst Decision
- ACIC Buy
- PLRX Hold
- Analyst Count
- ACIC 1
- PLRX 10
- Target Price
- ACIC $16.00
- PLRX $9.79
- AVG Volume (30 Days)
- ACIC 286.2K
- PLRX 1.5M
- Earning Date
- ACIC 08-06-2025
- PLRX 08-06-2025
- Dividend Yield
- ACIC 4.53%
- PLRX N/A
- EPS Growth
- ACIC 3.21
- PLRX N/A
- EPS
- ACIC 1.49
- PLRX N/A
- Revenue
- ACIC $302,261,000.00
- PLRX N/A
- Revenue This Year
- ACIC N/A
- PLRX N/A
- Revenue Next Year
- ACIC $37.63
- PLRX N/A
- P/E Ratio
- ACIC $7.50
- PLRX N/A
- Revenue Growth
- ACIC 23.92
- PLRX N/A
- 52 Week Low
- ACIC $8.82
- PLRX $1.10
- 52 Week High
- ACIC $15.08
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- ACIC 54.89
- PLRX 43.30
- Support Level
- ACIC $10.64
- PLRX $1.13
- Resistance Level
- ACIC $11.23
- PLRX $1.43
- Average True Range (ATR)
- ACIC 0.30
- PLRX 0.11
- MACD
- ACIC 0.08
- PLRX -0.01
- Stochastic Oscillator
- ACIC 83.19
- PLRX 37.57
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.